Table I.
Group | n | Normal mucosal, n (%) | Mild dysplasia, n (%) | Moderate-severe dysplasia, n (%) | OSCC, n (%) |
---|---|---|---|---|---|
Total | 100 | ||||
Wild-type control | 10 | 10 (100) | 0 (0) | 0 (0) | 0 (0) |
Prx1 knockout control | 10 | 10 (100) | 0 (0) | 0 (0) | 0 (0) |
Wild-type 4NQO | 20 | 0 (0) | 6 (30) | 14 (70) | 0 (0) |
Prx1 knockout 4NQO | 20 | 0 (0) | 7 (35) | 12 (50) | 1 (5) |
Wild-type 4NQO + H2O2 | 20 | 0 (0) | 1 (5) | 18 (90) | 1 (5) |
Prx1 knockout 4NQO + H2O2 | 20 | 0 (0) | 9 (45)a | 10 (50)a | 1 (5) |
P<0.05 vs. wild-type 4NQO + H2O2 group. OSCC, oral squamous cell carcinoma; Prx1, peroxiredoxin 1; 4NQO, 4-nitroquinoline-1-oxide.